CVT gets $175M For Half Of Lexiscan Royalties
This article was originally published in The Pink Sheet Daily
Executive Summary
Cash adds flexibility to Ranexa partner talks, company tells “The Pink Sheet” DAILY.
You may also be interested in...
Lexiscan Launch Gains CV Therapeutics $10M Milestone
Astellas license deal, royalty sale to TPG-Axon buoy CVT, but Ranexa anxiety lingers.
Lexiscan Launch Gains CV Therapeutics $10M Milestone
Astellas license deal, royalty sale to TPG-Axon buoy CVT, but Ranexa anxiety lingers.
Vertex Sells Lexiva, Agenerase Royalties For $160M
Non-core assets bring in cash for HCV push and more.